Baicalein Inhibits the SMYD2/RPS7 Signaling Pathway to Inhibit the Occurrence and Metastasis of Lung Cancer

Overview

Journal J Oncol

Specialty Oncology

Date 2022 Apr 18

PMID 35432530

Authors

Lin Gu

Feng Xu

Xiaoli Zhang

Zhihui Gu

Affiliations

Soon will be listed here.

Abstract

Objective: This study investigated the potential effects of Baicalein on proliferation, migration, and invasion of human lung cancer A549 and NCI-H1299 cells and its possible mechanisms.

Methods: The effects of Baicalein on proliferation and invasion of A549 and NCI-H1299 cells were detected by MTT assay, clonogenesis assay, and Transwell assay. A subcutaneous transplanted tumor model was used to evaluate the effects of SMYD2 and Baicalein on the proliferation of lung cancer. Baicalein inhibited in SMYD2/RPS7 signaling pathway in tumor cells was also detected by qRT-PCR.

Results: Baicalein significantly inhibited the growth of lung cancer cells. In addition, Baicalein significantly reduced the rate of A549 and NCI-H1299 cell invasion and clone formation in a dose-dependent manner. Animal experiments showed that both SMYD2 and Baicalein treatments could inhibit lung cancer tumor proliferation. Mechanism studies suggest that Baicalein inhibits the SMYD2/RPS7 signaling pathway.

Conclusion: These results indicated that Baicalein could inhibit the proliferation, migration, and invasion of LUNG cancer A549 and NCI-H1299 cells. Baicalein inhibits cell proliferation by downregulating the SMYD2/RPS7 signaling pathway.

Citing Articles

SMYD family in cancer: epigenetic regulation and molecular mechanisms of cancer proliferation, metastasis, and drug resistance.

Han T, Kim D, Son M, Cho H Exp Mol Med. 2024; 56(11):2325-2336.

PMID: 39482529 PMC: 11611910. DOI: 10.1038/s12276-024-01326-8.

Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway.

Chen T, Zhang P, Cong X, Wang Y, Li S, Wang H Front Pharmacol. 2024; 15:1405521.

PMID: 39144617 PMC: 11322074. DOI: 10.3389/fphar.2024.1405521.

Baicalein as Promising Anticancer Agent: A Comprehensive Analysis on Molecular Mechanisms and Therapeutic Perspectives.

Morshed A, Paul S, Hossain A, Basak T, Hossain M, Hasan M Cancers (Basel). 2023; 15(7).

PMID: 37046789 PMC: 10093079. DOI: 10.3390/cancers15072128.

Regulation of Cell Signaling Pathways and Non-Coding RNAs by Baicalein in Different Cancers.

Farooqi A, Kapanova G, Kalmakhanov S, Tanbayeva G, Zhakipbekov K, Rakhmetova V Int J Mol Sci. 2022; 23(15).

PMID: 35955525 PMC: 9368823. DOI: 10.3390/ijms23158377.

References

Naveenkumar C, Raghunandhakumar S, Asokkumar S, Devaki T . Baicalein abrogates reactive oxygen species (ROS)-mediated mitochondrial dysfunction during experimental pulmonary carcinogenesis in vivo. Basic Clin Pharmacol Toxicol. 2012; 112(4):270-81. DOI: 10.1111/bcpt.12025. View

Ashrafizadeh M, Zarrabi A, Hushmandi K, Hashemi F, Moghadam E, Owrang M . Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: Role of microRNAs and upstream mediators. Cell Signal. 2020; 78:109871. DOI: 10.1016/j.cellsig.2020.109871. View

Aryal P, Kim K, Park P, Ham S, Cho J, Song K . Baicalein induces autophagic cell death through AMPK/ULK1 activation and downregulation of mTORC1 complex components in human cancer cells. FEBS J. 2014; 281(20):4644-58. DOI: 10.1111/febs.12969. View

Komatsu S, Imoto I, Tsuda H, Kozaki K, Muramatsu T, Shimada Y . Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis. 2009; 30(7):1139-46. DOI: 10.1093/carcin/bgp116. View

Alam H, Gu B, Lee M . Histone methylation modifiers in cellular signaling pathways. Cell Mol Life Sci. 2015; 72(23):4577-92. PMC: 4628846. DOI: 10.1007/s00018-015-2023-y. View

Lee W, Loo C, Ghadiri M, Leong C, Young P, Traini D . The potential to treat lung cancer via inhalation of repurposed drugs. Adv Drug Deliv Rev. 2018; 133:107-130. DOI: 10.1016/j.addr.2018.08.012. View

Yu X, Yang Y, Li Y, Cao Y, Tang L, Chen F . Baicalein inhibits cervical cancer progression via downregulating long noncoding RNA BDLNR and its downstream PI3K/Akt pathway. Int J Biochem Cell Biol. 2017; 94:107-118. DOI: 10.1016/j.biocel.2017.11.009. View

Komatsu S, Ichikawa D, Hirajima S, Nagata H, Nishimura Y, Kawaguchi T . Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. Br J Cancer. 2014; 112(2):357-64. PMC: 4453442. DOI: 10.1038/bjc.2014.543. View

Chung H, Choi H, Seo E, Kang D, Oh E . Baicalin and baicalein inhibit transforming growth factor-β1-mediated epithelial-mesenchymal transition in human breast epithelial cells. Biochem Biophys Res Commun. 2015; 458(3):707-713. DOI: 10.1016/j.bbrc.2015.02.032. View

10.

Ferguson A, Larsen N, Howard T, Pollard H, Green I, Grande C . Structural basis of substrate methylation and inhibition of SMYD2. Structure. 2011; 19(9):1262-73. DOI: 10.1016/j.str.2011.06.011. View

11.

Yi X, Jiang X, Fang Z . Histone methyltransferase SMYD2: ubiquitous regulator of disease. Clin Epigenetics. 2019; 11(1):112. PMC: 6670139. DOI: 10.1186/s13148-019-0711-4. View

12.

Reynoird N, Mazur P, Stellfeld T, Flores N, Lofgren S, Carlson S . Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. Genes Dev. 2016; 30(7):772-85. PMC: 4826394. DOI: 10.1101/gad.275529.115. View

13.

Bie B, Sun J, Guo Y, Li J, Jiang W, Yang J . Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma. Biomed Pharmacother. 2017; 93:1285-1291. DOI: 10.1016/j.biopha.2017.07.068. View

14.

Wu L, Kou F, Ji Z, Li B, Zhang B, Guo Y . SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7. Cell Death Dis. 2021; 12(5):439. PMC: 8089105. DOI: 10.1038/s41419-021-03720-w. View

15.

Liu T, Gong W, Tan Z, Lu W, Wu X, Weng H . Baicalein inhibits progression of gallbladder cancer cells by downregulating ZFX. PLoS One. 2015; 10(1):e0114851. PMC: 4305301. DOI: 10.1371/journal.pone.0114851. View

16.

Yang Y, Liu K, Yang L, Zhang G . Bladder cancer cell viability inhibition and apoptosis induction by baicalein through targeting the expression of anti-apoptotic genes. Saudi J Biol Sci. 2018; 25(7):1478-1482. PMC: 6251996. DOI: 10.1016/j.sjbs.2017.03.014. View

17.

Shieh D, Liu L, Lin C . Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 2000; 20(5A):2861-5. View

18.

Ohtomo-Oda R, Komatsu S, Mori T, Sekine S, Hirajima S, Yoshimoto S . SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas. Hum Pathol. 2016; 49:145-55. DOI: 10.1016/j.humpath.2015.08.025. View

19.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

20.

Sun J, Li H, Ma H, Shi Y, Yin L, Guo S . SMYD2 promotes cervical cancer growth by stimulating cell proliferation. Cell Biosci. 2019; 9:75. PMC: 6749660. DOI: 10.1186/s13578-019-0340-9. View